Ketamine in Chronic Pain Management: An Evidence-Based Review
Ketamine in Chronic Pain Management: An Evidence-Based Review
Ketamine in Chronic Pain Management: An Evidence-Based Review
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
1732 REVIEW ARTICLE HOCKING AND COUSINS ANESTH ANALG<br />
REVIEW OF KETAMINE IN CHRONIC PAIN 2003;97:1730–9<br />
Table 2. Published Reports Concern<strong>in</strong>g <strong>Ketam<strong>in</strong>e</strong> Adm<strong>in</strong>istration <strong>in</strong> <strong>Chronic</strong> Persistent Pa<strong>in</strong><br />
Study<br />
Eide et al. (6)<br />
Fisher and Hagen (7)<br />
Vick and Lamer (8)<br />
Takahashi et al. (9)<br />
Design<br />
(<strong>Evidence</strong> level) Regimen Outcome Withdrawals/Side Effects<br />
9 Pts, R, DB, Sp<strong>in</strong>al cord <strong>in</strong>jury. K, AL or PL. Severity of cont<strong>in</strong>uous and 1—“bothersome dizz<strong>in</strong>ess.”<br />
(II)<br />
evoked pa<strong>in</strong> 2by K and AL.<br />
1 Pt, CR. 5-mo<br />
FU. (IV)<br />
1 Pt, CR. 9-mo<br />
FU (IV)<br />
1 Pt, CR. 8-mo<br />
FU (IV)<br />
Postcauda equ<strong>in</strong>a trauma.<br />
Haloperidol pretreatment 0.5 mg<br />
PO 4 hrly. K 10 mg sc bolus then<br />
3 mg/h 1to 5 mg/h. Changed to<br />
K10mg/8hPO1to 25 mg/8 h.<br />
Central poststroke pa<strong>in</strong>. Midazolam<br />
pretreatment, IV boluses<br />
(0.1 mg/kg) K to effect.<br />
Converted to oral dos<strong>in</strong>g 50 mg<br />
nightly then 50 mg/8 h.<br />
CRPS 2 from sciatic n. <strong>in</strong>jury. K<br />
0.3 mg/kg IV <strong>in</strong>effective and<br />
produced SE. Epidural K 0.3 mg/<br />
kg effective but SE—resolved<br />
after 24 h. Pa<strong>in</strong> returned at same<br />
time. Cont<strong>in</strong>uous <strong>in</strong>f. 25 g/kg/<br />
h effective without SE. Epidural<br />
removed after 10 days.<br />
L<strong>in</strong> et al. (10) 2 Pts, CR (IV) CRPS 1 of lower limbs K 7.5 mg,<br />
MO 0.75 mg and 0.1% B (6 mL)<br />
boluses via a lumbar epidural<br />
every 8 h—cont<strong>in</strong>ued 9–11 days<br />
while epidural rema<strong>in</strong>ed patent<br />
and free from signs of <strong>in</strong>fection,<br />
<strong>in</strong>tensive rehabilitation, 7 and 11<br />
treatments over 3 and 6 mo.<br />
Sorensen et al. (12) 31 F Pts, 3<br />
separate R,<br />
PLC, DB<br />
studies (II)<br />
Graven-Nielsen et al. (13) 29 F Pts, R,<br />
PLC, DB (II)<br />
Persson et al. (15)<br />
Backonja et al. (16)<br />
Max et al. (17)<br />
Felsby et al. (18)<br />
5F:3M Pts, R<br />
DB CO (II)<br />
4F:2M Pts, DB,<br />
PLC (II)<br />
8F Pts, R, PLC,<br />
DB CO (II)<br />
4F:6M Pts, R<br />
DB PLC (II)<br />
Gp1(n 9) received PL 2, MO<br />
10 mg or naloxone 0.8 mg IV<br />
over 10 m<strong>in</strong>–60 m<strong>in</strong> between<br />
drugs. Gp 2 (n 11) received L<br />
5 mg/kg or PL <strong>in</strong>fused over<br />
30 m<strong>in</strong> followed by 4 h<br />
observation—repeated daily for 1<br />
wk—CO after 1 wk WOP. Gp 3<br />
(n 11) received K 0.3 mg/kg or<br />
PL <strong>in</strong> similar protocol to Gp2.<br />
K 0.3 mg/kg IV or PL over 30 m<strong>in</strong><br />
on 2 separate days. Active drug<br />
50%2 pa<strong>in</strong> <strong>in</strong>tensity at rest on<br />
2 consecutive occasions identified<br />
17 K responders. 15 received DB<br />
<strong>in</strong>f of K or PL on two sessions<br />
separated by 1 wk WOP. Plasma<br />
K and norK levels analyzed.<br />
Lower extremity rest pa<strong>in</strong>. K 0.15,<br />
0.3, 0.45 mg/kg IV or MO 10 mg<br />
IV over 5 m<strong>in</strong> on 4 study days—<br />
at least 24 h WOP.<br />
Premedicated (lorazepam or<br />
midazolam). K 0.25 mg/kg IV or<br />
PL given over 5 m<strong>in</strong>. CO after<br />
4h.<br />
Posttraumatic neuropath pa<strong>in</strong>. K<br />
0.75 mg/kg/h, AL 1.5 g/kg/<br />
m<strong>in</strong> or PL IV for 2 h—doubled at<br />
60 m<strong>in</strong> and 90 m<strong>in</strong> if no benefit<br />
or m<strong>in</strong>imal SE—halved if SE.<br />
3 sessions with 24 h WOP. K<br />
0.2 mg/kg, MG 0.16 mmol/kg or<br />
PL IV over 10 m<strong>in</strong> then<br />
cont<strong>in</strong>uous <strong>in</strong>f. K 0.3 mg/kg, MG<br />
0.16 mmol/kg or PL.<br />
Broadley et al. (19) 2M Pts, CR (IV) Refractory neuropathic pa<strong>in</strong>. 1<br />
<strong>in</strong>itially controlled on K 0.2 mg/<br />
kg/h SC then converted to PO<br />
dos<strong>in</strong>g, 1as tolerated reach<strong>in</strong>g<br />
200 mg/6 h. 1 commenced<br />
25 mg/8 h 1over2wkto<br />
100 mg/6 h.<br />
Enarson et al. (20)<br />
13F:8M Pts, CS<br />
(IV)<br />
K 100 mg/day PO (40 mg <strong>in</strong><br />
sensitive pts) given <strong>in</strong> divided<br />
doses, 140 mg every 2 days until<br />
effective or SE limit<strong>in</strong>g. F<strong>in</strong>al<br />
doses 40–500 mg/day (median,<br />
220 mg).<br />
Walker and Cous<strong>in</strong>s (24) 1M, CR (IV) K <strong>in</strong>fusion 10 mg/h IV allowed<br />
<strong>in</strong>trathecal MO to be 2from<br />
32 mg/day to 2 mg/day; K<br />
ceased at day 20. MO withdrawal<br />
anticipated; oral clonid<strong>in</strong>e given.<br />
Pt self report. Pa<strong>in</strong> relieved at<br />
5 mg/h. Persistent benefit<br />
from K po—other analgesics<br />
stopped.<br />
VAS 9/10 pretreatment. VAS<br />
3/10 posttreatment. Susta<strong>in</strong>ed<br />
effect. Other therapeutic<br />
drugs withdrawn.<br />
Pa<strong>in</strong> relief and disappearance of<br />
mechanical allo persisted<br />
dur<strong>in</strong>g FU. Autonomic<br />
features not abolished.<br />
Almost complete resolution of<br />
pa<strong>in</strong> and autonomic<br />
dysfunction.<br />
Gp 1—no significant changes.<br />
Gp 2—reduction <strong>in</strong> pa<strong>in</strong> both<br />
dur<strong>in</strong>g and after the <strong>in</strong>f. Gp<br />
3—significant 2 pa<strong>in</strong><br />
<strong>in</strong>tensity, tenderness at tender<br />
po<strong>in</strong>ts, 1 endurance.<br />
2referred pa<strong>in</strong>, temporal<br />
summation, muscular<br />
hyperalgesia and muscle pa<strong>in</strong><br />
at rest.<br />
Dose-dependent analgesic effect<br />
of K with transient complete<br />
pa<strong>in</strong> relief <strong>in</strong> all at largest dose.<br />
5-complete relief with M; 3—<br />
little or no relief.<br />
3/6 50% 2 pa<strong>in</strong>, allo and<br />
hyperalgesia for 2–3 h.1/6—<br />
no relief from pa<strong>in</strong> but 2allo<br />
and hyperalgesia.<br />
K signif. 2pa<strong>in</strong> and allo (P <br />
0.01). AL 2allo (P 0.01) but<br />
not background pa<strong>in</strong>.<br />
K—signif 2 pa<strong>in</strong> (57%) and allo<br />
(33%). MG—non-signif 2<br />
pa<strong>in</strong> (29%) and allo (18%).<br />
Pa<strong>in</strong> free until GI illness<br />
prevented PO<br />
dos<strong>in</strong>g—converted to SC until<br />
death 1 mo later. Pa<strong>in</strong> free for<br />
3 mo, then symptoms<br />
returned—fleca<strong>in</strong>ide used<br />
with success for 2 mo then K<br />
restarted—Pa<strong>in</strong> free without<br />
SE until report<strong>in</strong>g (4 mo).<br />
Only 4 cont<strong>in</strong>ued K over 1 yr<br />
with improved 2 pa<strong>in</strong> and<br />
2analgesic use; even these<br />
eventually discont<strong>in</strong>ued K<br />
because of an unfavourable<br />
benefit versus SE ratio.<br />
Susta<strong>in</strong>ed reduction <strong>in</strong><br />
hyperalgesia, <strong>in</strong>trathecal MO.<br />
Dose slowly <strong>in</strong>creased over<br />
next 12 mo to half previous<br />
dose (15 mg/day).<br />
Bolus caused brief “float<strong>in</strong>g/<br />
dream<strong>in</strong>g” sensation, sc<br />
sites changed daily because<br />
of erythema.<br />
Dysphoria, confusion and<br />
depression refractory to<br />
benzodiazep<strong>in</strong>es if dose<br />
<strong>in</strong>creased above 150 mg/day.<br />
Initial SE not specified.<br />
Transient headache, nausea<br />
and discomfort after<br />
epidural adm<strong>in</strong>istration.<br />
Not documented.<br />
Gp 1: 7/9; Gp 2: 3/11; Gp 3:<br />
10/11 had transient<br />
(15 m<strong>in</strong>) SE after K.<br />
Unreality, dizz<strong>in</strong>ess,<br />
auditory change.<br />
2 withdrew—unrelated<br />
reasons, 12 failed to<br />
respond <strong>in</strong>itially. SE not<br />
documented.<br />
Disturbed cognition and<br />
perception were<br />
pronounced and dose<br />
dependant.<br />
5/6 had SE dur<strong>in</strong>g K;<br />
diplopia, nystagmus<br />
psychomimetic SE, 1HR/<br />
BP.<br />
SE always preceded<br />
analgesia and persisted<br />
beyond return of pa<strong>in</strong> after<br />
stopp<strong>in</strong>g <strong>in</strong>f.<br />
HR and BP with<strong>in</strong> 20% of<br />
basel<strong>in</strong>e. Psychomimetic SE<br />
7/10 after K. Heat and pa<strong>in</strong><br />
at <strong>in</strong>jection site from MG.<br />
Vivid, not unpleasant<br />
dream<strong>in</strong>g.<br />
9 discont<strong>in</strong>ued with<strong>in</strong> 2 wk—<br />
<strong>in</strong>tolerable psychomimetic<br />
SE, 4—few SE but m<strong>in</strong>imal<br />
benefit, 4—equivocal<br />
response.<br />
Mild halluc<strong>in</strong>ations on 3<br />
occasions—controlled by<br />
temporary 2ketam<strong>in</strong>e<br />
<strong>in</strong>fusion rate.